CASTOR

8:25
The definitive guide to multiple myeloma at ASH 2018: part I
Mohamad Mohty et al.
2:21
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Maria-Victoria Mateos
3:08
Carfilzomib for relapsed multiple myeloma: clinical trial updates
Katja Weisel
1:22
The importance of MRD status in MM
Niels van de Donk
1:54
CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
Katja Weisel
2:42
Promising results for daratumumab in the front line setting
Philippe Moreau
3:22
Unprecedented clinical trial results for MM
Alberto Rocci
3:34
How effective are monoclonal antibodies at improving overall survival?
Philippe Moreau
1:56
Effective antibody therapy and updates from the POLLUX and CASTOR trials
Meletios Dimopoulos
2:13
Daratumumab in the treatment of multiple myeloma
Paul Richardson
3:19
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Nikhil Munshi
4:43
Immunotherapy highlights in multiple myeloma at ASH 2016
Niels van de Donk
4:11
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
Joseph Mikhael
3:51
Daratumumab in multiple myeloma: an overview of 3 key trials
Niels van de Donk
2:58
Why daratumumab is effective in multiple myeloma – results from the CASTOR trial
Antonio Palumbo
3:12
Results of Phase III POLLUX trial on daratumumab in multiple myeloma
Noopur Raje
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals